New Business Ventures, Quarterly Dividends, and Stock Price Movements - Research Report on Merck, Bristol-Myers Squibb,

   New Business Ventures, Quarterly Dividends, and Stock Price Movements -
 Research Report on Merck, Bristol-Myers Squibb, DENTSPLY, Pharmacyclics, and
                               St. Jude Medical

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 25, 2013

NEW YORK, December 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck &
Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY), DENTSPLY
International Inc. (NASDAQ: XRAY), Pharmacyclics Inc. (NASDAQ: PCYC), and St.
Jude Medical Inc. (NYSE: STJ). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Merck & Co., Inc. Research Report

On December 20, 2013, Merck & Co., Inc. (Merck) announced the launch of a new
business centeredon providing comprehensive, evidence-based weight management
interventions in the US. According to the Company, this business is based on
providing weight management interventions for employers, hospitals, medical
groups, health plans, and patients, bringing together a structured diet,
behavior coaching and monitoring, and physical activity to achieve clinically
meaningful weight loss, thereby reducing the risk of chronic illnesses,
including diabetes and cardiovascular disease. The Company informed that HMR
Weight Management Service Corporation, a new company that brings together the
capabilities of Merck and assets from Health Management Resources Corporation
(HMR), was created to bring these interventions to the market more
effectively. Merck added that HMR will operate as a subsidiary of the Company.
The Full Research Report on Merck & Co., Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

Bristol-Myers Squibb Co. Research Report

On December 19, 2013, Bristol-Myers Squibb Co. (Bristol-Myers Squibb)
announced that the Company's Board of Directors declared a quarterly dividend
of $0.36 per share on the $0.10 par value Common Stock of the corporation for
Q1 FY 2014. Bristol-Myers Squibb reported that the said dividend will be
payable on February 3, 2014 to stockholders of record at the close of business
on January 3, 2014. The Company's Board of Directors further declared a
quarterly dividend of $0.50 per share on the $2.00 Convertible Preferred stock
of the corporation, payable March 3, 2014 to stockholders of record at the
close of business on February 7, 2014. The Full Research Report on
Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

--

DENTSPLY International Inc. Research Report

On December 20, 2013, DENTSPLY International Inc.'s (DENTSPLY) stock rose
0.21%, ending the day at $48.43. Over the previous three trading sessions,
shares of DENTSPLY gained 2.04%, compared to the Nasdaq Composite which gained
2.01% during the same period. The Full Research Report on DENTSPLY
International Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/6b01_XRAY

--

Pharmacyclics Inc. Research Report

On December 20, 2013, Pharmacyclics Inc.'s (Pharmacyclics) stock rose 2.41%,
ending the day at $103.85. Over the previous three trading sessions, shares of
Pharmacyclics gained 4.16%, compared to the Nasdaq Composite which gained
2.01% during the same period. The Full Research Report on Pharmacyclics Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/df74_PCYC

--

St. Jude Medical Inc. Research Report

On December 18, 2013, St. Jude Medical Inc. (St. Jude Medical) announced that
the Company is scheduled to present at the 32^nd Annual J.P. Morgan Healthcare
Conference on January 13, 2014, in San Francisco. The Company's Chairman,
President and CEO, Daniel J. Starks, will address the conference at 11:00 a.m.
PST. St. Jude Medical also informed that interested parties may access a live
webcast of the presentation at the Company website. The Full Research Report
on St. Jude Medical Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b338_STJ

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)